Opthea Ltd Files September 2024 Corporate Presentation

Ticker: OPTEY · Form: 6-K · Filed: Sep 9, 2024 · CIK: 1815620

Sentiment: neutral

Topics: corporate-presentation, biotech, filing-update

TL;DR

Opthea dropped its Sept 2024 corporate deck. Check it for pipeline updates and strategy.

AI Summary

Opthea Limited filed a Form 6-K on September 9, 2024, to report its corporate presentation for September 2024. The filing includes a press release detailing the presentation, which likely covers the company's business, financial status, and strategic outlook. Opthea is a biotechnology company focused on developing novel therapies for serious eye diseases.

Why It Matters

This filing provides investors with an updated overview of Opthea's progress and strategic direction, crucial for understanding the company's valuation and future prospects in the competitive biopharmaceutical market.

Risk Assessment

Risk Level: medium — As a clinical-stage biotechnology company, Opthea faces inherent risks related to drug development, regulatory approvals, and market adoption.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report Opthea Limited's corporate presentation for September 2024, which includes a press release detailing the presentation.

What type of company is Opthea Limited?

Opthea Limited is a company in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, with SIC code 2836.

When was this report filed with the SEC?

This report was filed with the SEC on September 9, 2024.

What exhibit is included with this 6-K filing?

Exhibit 99.1 is included, which is a Press Release titled 'Opthea Corporate Presentation - Sept 2024'.

Where is Opthea Limited's principal executive office located?

Opthea Limited's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.

Filing Stats: 148 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-09-09 06:05:53

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 09/09/2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing